(Q31017419)

15 November 2017

0 references

Biologics in inflammatory bowel disease: what are the data? (English)

1 reference

inflammatory bowel diseases

15 November 2017

0 references

author

Jean-Frédéric Colombel

4

object named as

Jean-Frédéric Colombel

1 reference

15 November 2017

Justin Côté-Daigneault

1

1 reference

15 November 2017

Mickael Bouin

2

1 reference

15 November 2017

Raymond Lahaie

3

1 reference

15 November 2017

Pierre Poitras

5

1 reference

15 November 2017

1 October 2015

1 reference

United European gastroenterology journal

15 November 2017

1 reference

15 November 2017

3

1 reference

15 November 2017

5

1 reference

15 November 2017

419-428

1 reference

Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis

15 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4625751

Vedolizumab as induction and maintenance therapy for Crohn's disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4625751

Vedolizumab as induction and maintenance therapy for ulcerative colitis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4625751

Clinical effects of adalimumab treatment with concomitant azathioprine in Japanese Crohn's disease patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4625751

Ustekinumab induction and maintenance therapy in refractory Crohn's disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4625751

Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4625751

Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4625751

Certolizumab pegol for the treatment of Crohn's disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4625751

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4625751

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4625751

Infliximab for induction and maintenance therapy for ulcerative colitis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4625751

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4625751

Infliximab maintenance therapy for fistulizing Crohn's disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4625751

Natalizumab for active Crohn's disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4625751

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4625751

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

21 June 2018

1 reference

https://api.crossref.org/works/10.1177%2F2050640615590302

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2050640615590302

Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2050640615590302

Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2050640615590302

Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2050640615590302

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2050640615590302

Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2050640615590302

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2050640615590302

Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2050640615590302

Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2050640615590302

Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2050640615590302

Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2050640615590302

Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2050640615590302

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2050640615590302

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2050640615590302

Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis

21 January 2018

1 reference

12 December 2020

Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease

1 reference

12 December 2020

Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study

1 reference

12 December 2020

Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study

1 reference

12 December 2020

Maintenance therapy with certolizumab pegol for Crohn's disease

1 reference

12 December 2020

Tumour-necrosis-factor antibody treatment in Crohn's disease

1 reference

12 December 2020

Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial

1 reference

12 December 2020

Identifiers

DOI

10.1177/2050640615590302

1 reference

15 November 2017

1 reference

15 November 2017

PubMed publication ID

26535119

1 reference